Product Program year 2025 Source: CMS Open Payments

Furoscix

Drug Cardiology

NDC 71767-100-01

Open in the dashboard

General payments

$2,890,131

39,539 payments

Research payments

$641,719

6 payments

Through program year 2025, $2,890,131 in general payments and $641,719 in research payments were reported against Furoscix (Cardiology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2025 General $1,277,744 19,043
2024 General $974,217 13,365
2024 Research $641,719 6
2023 General $638,170 7,131

Breakdown

Who paid General payments · program years 2023–2025
  1. Scpharmaceuticals Inc. $2,889,861 39,527 payments
  2. Shorla Oncology Inc. $270 12 payments
Top recipients General payments · program year 2025
  1. Hunter Champion Cardiovascular Disease · Columbus, GA $130,461 10% · 94 payments
  2. Gautam Shah Cardiovascular Disease · Fairview Park, OH $51,764 4% · 56 payments
  3. William Abraham Advanced Heart Failure and Transplant Cardiology · Columbus, OH $43,127 3% · 5 payments
  4. Benjamin Kalsmith Cardiovascular Disease · Pgh, PA $41,037 3% · 32 payments
  5. John Ryan Cardiovascular Disease · Salt Lake City, UT $31,974 3% · 24 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Cardiovascular Disease Internal Medicine $566,041 47% · 2,094 practitioners
  2. Advanced Heart Failure and Transplant Cardiology Internal Medicine $153,775 13% · 160 practitioners
  3. Nephrology Internal Medicine $101,683 8% · 1,224 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $77,654 6% · 1,362 practitioners
  5. Interventional Cardiology Internal Medicine $66,495 5% · 719 practitioners

The top 5 of 107 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Georgia $168,396 13% · 385 recipients
  2. Pennsylvania $128,759 10% · 602 recipients
  3. New York $128,381 10% · 981 recipients
  4. Ohio $113,404 9% · 315 recipients
  5. Texas $106,718 8% · 994 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

994

Prescriptions dispensed, refills included

Drug cost

$6,318,016

Paid at the pharmacy, in all

Prescribers

61

With 11 or more claims of it

Medicare Part D drugs matched to FUROSCIX, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Furoscix Furosemide Same name 61 994 $6,318,016

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 61 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Marenda Russell Nurse Practitioner GA 37 $227,056 $101
Amanda Edgar Nurse Practitioner MS 36 $258,802 $2,582
Randeep Suneja Cardiology TX 30 $213,680 $42
Paul Ritter Nurse Practitioner KY 27 $166,074 $174
Vamsi Krishna Interventional Cardiology TX 26 $125,944 $28,830

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 61 with Patron
39,539 general · 6 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record